At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Ruxolitinib 25 mg +1 moredrug
Likely dose
Ruxolitinib 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib 25 mg and Dexamethasone 40 mg for Multiple Myeloma. Completed, enrolled 13 participants across 3 sites.
Detailed Summary
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionJul 2010
TodayJul 2026
First PostedMar 19, 2008
Enrollment StartMar 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.3 years ago
Interventions
Ruxolitinib 25 mgdrug
Ruxolitinib was supplied as 5 and 25 mg tablets.
Dexamethasone 40 mgdrug
Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.